Scholarlink

<p>Effective activation of innate and adaptive immunity remains a major challenge in cancer immunotherapy. In this study, we aimed to develop an immunostimulatory oligonucleotides for antitumor immunotherapy. We designed branched Y-shaped DNA (Yb-DNA) nanoparticles complexed with a reducible polycationic carrier (RPC-bPEI<sub>0.8kDa</sub>), which we named YbNano, to enhance intracellular delivery and immune activation. The immunostimulatory activity of YbNano was determined in mouse bone marrow-derived dendritic cells. The efficacy of YbNano for antitumor immunotherapy was investigated using a melanoma allograft mouse model and a lung metastasis of breast cancer mouse model. YbNano exhibited uniform particle morphology and efficient cellular uptake in dendritic cells. YbNano induced robust expression of type I interferon (IFN-β), interleukin-12 (IL-12), chemokines such as CXCL10, and costimulatory molecules (CD80, CD86) in dendritic cells, promoting CD8⁺ T cell differentiation. In preclinical cancer models, intravenous administration of YbNano potentiated the efficacy of anti-PD-L1 therapy in B16F10 melanoma-bearing C57BL/6 mice and enhanced the therapeutic outcomes of doxorubicin or anti-PD-L1 treatment in suppressing lung metastasis in 4T1 breast cancer-bearing BALB/c mice. YbNano functions as a dual activator of cGAS/STING and TLR9, orchestrating dendritic cell activation and amplifying downstream innate and adaptive immune responses in tumor microenvironment. Collectively, these findings suggest that YbNano represents a rationally engineered, multifunctional nucleic acid-based immunotherapeutic agent with the potential to modulate the tumor microenvironment and to augment responses when used in combination cancer therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nanostructured branched Y-DNA promotes antitumor immunity through dual activation of cGAS/STING and TLR9

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月18日

查看全文
  • Jin Kyung Seok,
  • Jung In Jee,
  • Jong Han Oh,
  • So Yeon Ahn,
  • Hana Cho,
  • Young Eun Yang,
  • Minhyuk Kim,
  • Hyung-Joo Kwon,
  • Yong-Yeon Cho,
  • Hye Suk Lee,
  • Soong Ho Um,
  • Han Chang Kang,
  • Joo Young Lee

摘要

Effective activation of innate and adaptive immunity remains a major challenge in cancer immunotherapy. In this study, we aimed to develop an immunostimulatory oligonucleotides for antitumor immunotherapy. We designed branched Y-shaped DNA (Yb-DNA) nanoparticles complexed with a reducible polycationic carrier (RPC-bPEI0.8kDa), which we named YbNano, to enhance intracellular delivery and immune activation. The immunostimulatory activity of YbNano was determined in mouse bone marrow-derived dendritic cells. The efficacy of YbNano for antitumor immunotherapy was investigated using a melanoma allograft mouse model and a lung metastasis of breast cancer mouse model. YbNano exhibited uniform particle morphology and efficient cellular uptake in dendritic cells. YbNano induced robust expression of type I interferon (IFN-β), interleukin-12 (IL-12), chemokines such as CXCL10, and costimulatory molecules (CD80, CD86) in dendritic cells, promoting CD8⁺ T cell differentiation. In preclinical cancer models, intravenous administration of YbNano potentiated the efficacy of anti-PD-L1 therapy in B16F10 melanoma-bearing C57BL/6 mice and enhanced the therapeutic outcomes of doxorubicin or anti-PD-L1 treatment in suppressing lung metastasis in 4T1 breast cancer-bearing BALB/c mice. YbNano functions as a dual activator of cGAS/STING and TLR9, orchestrating dendritic cell activation and amplifying downstream innate and adaptive immune responses in tumor microenvironment. Collectively, these findings suggest that YbNano represents a rationally engineered, multifunctional nucleic acid-based immunotherapeutic agent with the potential to modulate the tumor microenvironment and to augment responses when used in combination cancer therapy.